- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03173300
Natural History Study Protocol in PMM2-CDG (CDG-Ia)
Clinical and Basic Investigations Into Phosphomannomutase Deficiency (PMM2-CDG)
Clinical and Basic Investigations into Phosphomannomutase deficiency (PMM2-CDG)
This is a natural history (observational) protocol designed to collect clinical and biological information in patients with PMM2-CDG (CDG-Ia).
Study Overview
Status
Conditions
Detailed Description
Subjects enrolled in this natural history study will be thoroughly examined for signs and symptoms of PMM2-CDG. Medical history, physical examination, laboratory testing and imaging studies will be performed during a single consultation. Follow-up will occur every 6 months at a minimum, depending on the standard of care at the investigator's institution as well as the clinical status of the individual patient. All medical procedures are routine. No new therapy is offered as part of this study, and no change in the patients' routine therapy is dictated by this protocol. No randomization will be performed.
All serious and non-serious adverse events will be recorded in the study CRF database.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Leuven, Belgium
- University Hospital Leuven
-
-
-
-
-
Prague, Czechia
- General University Hospital in Prague
-
-
-
-
-
Paris, France
- Necker Enfants-Malades Hospital
-
-
-
-
-
Catania, Italy
- University Hospital of Catania
-
-
-
-
-
Nijmegen, Netherlands
- Radboud University Nejmegen Medical Center
-
-
-
-
-
Warsaw, Poland
- Mother and Child Institute (Instytut Matki i Dziecka)
-
-
-
-
-
Porto, Portugal
- Centro Hospitalar do Porto
-
-
-
-
-
Barcelona, Spain
- Hospital Sant Joan de Deu
-
-
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Tulane University Medical Center
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic College of Medicine
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Children's Hospital of Philadelphia (CHOP)
-
Pittsburgh, Pennsylvania, United States, 15224
- Children's Hospital of Pittsburgh
-
-
Washington
-
Seattle, Washington, United States, 98105
- Seattle Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Informed consent/assent by the patient and/or their legally authorized representative
- Confirmed diagnosis of PMM2-CDG, based on enzymatic or molecular tests
- Willing and able to adhere to study requirements described in the protocol and consent/assent documents
Exclusion Criteria:
- Known or suspected differential diagnosis of any other known CDG (not PMM2-CDG)
- Currently using investigational drug
- Blood loss of >250 mL or donated blood within 56 days, or donated plasma within 7 days, of study screening
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
collect clinical and biological information in patients with CDG-PMM2
Time Frame: up to 4 years
|
up to 4 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Horacio Plotkin, MD / Chief Medical Officer, Glycomine, Inc.
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Phosphomannomutase 2 Deficiency
-
Maggie's Pearl, LLCActive, not recruitingPmm2-CDG | Phosphomannomutase 2 Deficiency | Phosphomannomutase 2 Congenital Disorder of Glycosylation | Phosphomannomutase II Congenital Disorder of Glycosylation | Phosphomannomutase II DeficiencyUnited States
-
Horizon Pharma USA, Inc.CompletedAldehyde Dehydrogenase-2 (ALDH2) DeficiencyUnited States
-
Northwell HealthCompletedType 2 Diabetes Mellitus | Vitamin B12 DeficiencyUnited States
-
Oregon Health and Science UniversityUniversity of PittsburghCompletedVery Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency | Carnitine Palmitoyltransferase 2 (CPT2) Deficiency | Mitochondrial Trifunctional Protein (TFP) Deficiency | Long-chain 3 hydroxyacylCoA Dehydrogenase (LCHAD) DeficiencyUnited States
-
Oregon Health and Science UniversityCompletedTrifunctional Protein Deficiency | Very Long Chain Acyl Coa Dehydrogenase Deficiency | Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency | Carnitine Palmitoyltransferase Deficiency 2United States
-
Ohio State UniversityCompletedAnemia | Type 2 Diabetes | Neuropathy | Vitamin B12 DeficiencyUnited States
-
Tan Tock Seng HospitalNational Healthcare Group, Singapore; Duke-NUS Graduate Medical SchoolCompletedVitamin D Deficiency | Diabetes Mellitus Type 2Singapore
-
Columbia UniversityUniversitat Autonoma de Barcelona; Instituto de Salud Carlos III; University... and other collaboratorsActive, not recruitingThymidine Kinase 2 Deficiency | Mitochondrial DNA Depletion Syndrome 2 Myopathic TypeUnited States
-
Oregon Health and Science UniversityCompletedTrifunctional Protein Deficiency | Carnitine Palmitoyltransferase 2 Deficiency | Very Long-chain Acyl-CoA Dehydrogenase Deficiency | Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency
-
University of FloridaCompletedType 2 DiabetesUnited States